Clinical trial Recruiting at 1 site Interventional Ages 65 to 90

Remimazolam vs. Propofol for Sedation After Cardiac Surgery in Older Adults

Official title: Effects of Remimazolam Tosylate Versus Propofol for Postoperative Sedation on the Incidence of Postoperative Delirium in Older Patients Undergoing Cardiac Surgery: A Prospective, Double-Blind, Randomized Controlled Trial

Run by Nanjing First Hospital, Nanjing Medical University · NCT07908121 · Data updated 2026-11-12

This trial tests whether remimazolam tosylate can lower the rate of postoperative delirium compared with propofol in patients 65 and older after cardiac surgery with bypass.

More Delirium - Postoperative trials

Quick facts

Study typeInterventional
Ages65 Years to 90 Years
SexAll
Enrollment600 (estimated)
SponsorNanjing First Hospital, Nanjing Medical University
Academic / other
Locations1 site (Nanjing, Jiangsu)
StatusRecruiting
StartedSeptember 5, 2026
Main results expectedDecember 23, 2027
Study endsDecember 30, 2027
Registry record updatedOctober 30, 2026
Trial IDNCT07908121 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 65 and older undergoing elective cardiac surgery with bypass and anticipated need for mechanical ventilation and sedation for at least 2 hours in the cardiac surgery ICU.

Probably not a fit

Patients with preexisting delirium, severe dementia, certain complex or emergent cardiac procedures, or severe alcohol use disorder may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, prospective, randomized, double-blind, double-dummy, active-controlled superiority trial enrolling 600 patients aged 65 or older undergoing elective cardiac surgery with cardiopulmonary bypass. Participants are randomized 1:1 to receive either remimazolam tosylate or propofol for continuous ICU sedation, with dose adjustments to maintain a target RASS of -2 to 0 and standardized analgesia. The primary aim is to determine if remimazolam tosylate reduces the incidence of postoperative delirium compared with propofol. The study excludes emergency surgeries, certain complex cardiac procedures, severe psychiatric conditions, dementia, and recent substantial alcohol misuse. Outcomes include delirium incidence and safety under standardized postoperative care in the ICU.

Why it matters

Potential benefit: If successful, remimazolam tosylate could reduce postoperative delirium and improve recovery after cardiac surgery in older adults.

How similar studies have gone: Randomized trials in anesthesia have explored alternative sedatives for delirium, with some showing potential delirium reduction, but data specific to remimazolam in this setting are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria

1\. Age ≥65 years. 2. Undergoing elective cardiac surgery with cardiopulmonary bypass, including coronary artery bypass grafting (CABG), valve surgery, or combined CABG and valve surgery.

3\. Admission to the cardiac surgery intensive care unit (ICU) after surgery, with an anticipated need for invasive mechanical ventilation and continuous sedation for at least 2 hours.

4\. Written informed consent obtained from the participant or their legally authorized representative.

5\. No delirium identified during the preoperative assessment. Exclusion Criteria

1. Emergency or salvage cardiac surgery.
2. Heart transplantation, ventricular assist device implantation, surgery for aortic dissection requiring deep hypothermic circulatory arrest, or other cardiac procedures outside the scope of this study.
3. Severe psychiatric disorders, diagnosed Alzheimer's disease or dementia, or preoperative delirium.
4. Severe alcohol use disorder or a history of severe alcohol misuse.
5. Previous cerebrovascular events or other conditions causing severe visual, hearing, or communication impairment that would prevent reliable delirium assessment despite appropriate assistance.
6. Known hypersensitivity or contraindications to either study drug or its excipients, or severe hepatic or renal failure.
7. Decompensated acute circulatory failure or hemodynamic instability at the time of randomization.
8. Concurrent participation in another interventional clinical trial that could affect the primary outcome.

Where it's running

  • Nanjing First Hospital
    Nanjing, Jiangsu, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.